Hey guys, how long to #flowcytometry abs last in room temperature? Asking for a friend who had a fridge disconnected by accident. Yes that someone is me. Ran experiment but saw zero signals for some flours i expect to be positive.

Looking for T cell biologists who would like to join a research program dedicated to develop cellular therapeutics against HPV cancer! #hpv #tcells #immunotherapy MD Anderson Cancer Center #postdocjobs

Dr. Nils-Petter Rudqvist is one of the newest faculty members of GSBS affiliated to the Immunology Program. Dr. Rudqvist started his lab amidst the pandemic last year and is looking for students and trainees! Follow him on Twitter Nils-Petter Rudqvist

cancercareers.org/jobs/65604189-… postdocs, apply and come work with me on T cell therapeutics at the world's largest medical center and the #1 cancer center in the world! #aacr #postdocjobs

Great work on HPV integration in 105 oropharyngeal tumors by Symer/Gillison. Expression of genes close to integration sites increased up to 86-fold. An integration site close to PD-L1 was found, potentially impacting immune evasion...! MD Anderson Cancer Center biorxiv.org/content/10.110…

The recent paper from Kellie N. Smith on Ag specific T cells in NSCLC pts is a wealth of data and we will learn so much from it. Their willingness to share really well structured raw data is well worth celebrating. Please take not people - this is how it's done. #teamscience

Tomorrow you can listen in as Dr. Vadim Chumak from Ukraine gives an update on the radiological situation as it relates to the Ukraine's nuclear reactors. radres.org/news/598619/Sp… #StandWithUkraine

Hey all #immunologists, anyone know the actual domain (epitope in AA) recognized by the H57-597 mouse TCR constant region Ab? #immunotherapy

Happy to share our recent work on developing RT and immunotherapy combo tx! Take home msg: 1) hypo-fx RT drive T cells into cold tumors; 2) together RT/CTLA4 induces uniquely functional T cell subsets; 3) CD40 is really very important Weill Cornell Medicine MD Anderson Cancer Center

Hi Society for Immunotherapy of Cancer members! I am really excited to be presenting our first abstract coming out of my lab at MD Anderson Cancer Center during the clinical rapid oral presentation at 11:55a in ballroom west! I will tell you about our tcr/epitope discovery pipeline and our findings so far. #SITC22

I am pleased to announce that as of July, I joined Agenus as a Director! Here, I will continue my career goal of developing novel immunotherapy strategies with the potential of curing patients with cancer. #cancerresearch #immunotherapy

Our paper on RT+CTLA4+CD40 in hard-to-treat tumors is out in Nature Communications! In-depth analysis of 4T1 tumors treated with RT+CTLA4 and demonstration of CD40 as best companion IO in this setting. Thanks to all co-authors and especially maud charpentier and Sandra Demaria!

Rudqvist and Charpentier et al. demonstrated that radiation therapy plus anti-CTLA-4 (RT+CTLA4i) enhanced intratumoral TCR clonality and divergence, decreased Tregs, and increased effector memory [...] bit.ly/3r6t0N9  Nils-Petter Rudqvist maud charpentier Sandra Demaria

🗞️Forbes Published today! Are we on the verge of a new drug combo for colorectal cancer? Read more about our work on this immunotherapy called the BOT (Botensilimab). We describe this “inside-out”🌊 wave of regression by immune cells. Alex Knapp forbes.com/sites/alexknap…

Have a look at these responses - case report of two pts. Amazing to see neoadjuvant IO help pts!

Last week we published a commentary on next gen aCTLA-4 molecules. Agenus botensilimab is an advanced molecule in this class that modulates both innate and adaptive immune cells, distinguishing it from 1st gen aCTLA-4 molecules. #immunotherapy doi.org/10.1080/216240…

Revolutionizing Cancer Immunotherapy: Next-Gen CTLA-4 Targeting and Combination Therapies oncodaily.com/insight/21345.… Dhan Chand Manushak Avagyan Nils-Petter Rudqvist Agenus #CancerResearch #Immunotherapy #MedicalInnovation #Oncology #Healthcare #OncTwitter #OncoDaily

Excited to fully support Dr. Sandra Demaria for SITC VP! Her dedication to patients as a translational scientist is inspiring. She takes on challenges and leads with compassion. I'm excited about her bringing the energy and expertise to the VP role! #sitc #immunotherapy